913835-68-4 Usage
Description
1-(TERT-BUTYLDIMETHYLSILYL)-1H-INDOL-5-YLBORONIC ACID 97 is a chemical compound that serves as an intermediate in the synthesis of various organic compounds. It is characterized by its unique structure, which includes a tert-butyldimethylsilyl group and an indol-5-ylboronate moiety. 1-(TERT-BUTYLDIMETHYLSILYL)-1H-INDOL-5-YLBORONIC ACID 97 is known for its reactivity and stability, making it a valuable building block in organic chemistry.
Uses
Used in Pharmaceutical Industry:
1-(TERT-BUTYLDIMETHYLSILYL)-1H-INDOL-5-YLBORONIC ACID 97 is used as a key intermediate in the synthesis of 1H-Pyrazolo[3,4-d]pyrimidine, 7H-Pyrrolo[2,3-d]pyrimidine, and Pyrrolo[2,1-f][1,2,4]triazine derivatives. These compounds are selective Brk kinase inhibitors, which have potential applications in the prevention or treatment of various types of cancers.
In the pharmaceutical industry, 1-(TERT-BUTYLDIMETHYLSILYL)-1H-INDOL-5-YLBORONIC ACID 97 plays a crucial role in the development of novel therapeutic agents targeting Brk kinase, a protein involved in cell proliferation and survival. By inhibiting Brk kinase, these derivatives can potentially suppress the growth of cancer cells and contribute to the advancement of cancer treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 913835-68-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,8,3 and 5 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 913835-68:
(8*9)+(7*1)+(6*3)+(5*8)+(4*3)+(3*5)+(2*6)+(1*8)=184
184 % 10 = 4
So 913835-68-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H22BNO2Si/c1-14(2,3)19(4,5)16-9-8-11-10-12(15(17)18)6-7-13(11)16/h6-10,17-18H,1-5H3
913835-68-4Relevant articles and documents
Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors
Walter, Isabell,Adam, Sebastian,Gentilini, Maria Virginia,Kany, Andreas M.,Brengel, Christian,Thomann, Andreas,Sparwasser, Tim,K?hnke, Jesko,Hartmann, Rolf W.
, p. 2786 - 2801 (2021)
CYP121 of Mycobacterium tuberculosis (Mtb) is an essential target for the development of novel potent drugs against tuberculosis (TB). Besides known antifungal azoles, further compounds of the azole class were recently identified as CYP121 inhibitors with
